InDream Healthcare

InDream Healthcare, based in South Korea, specializes in enhancing healthcare delivery through innovative clinical decision support systems that streamline medication reviews and minimize medical disputes. InDream Healthcare provides a Clinical Decision Support System to assist healthcare professionals in the medication review process. Founded in 2022 in Jeju-si, South Korea, the company has executed one deal to date, with the most recent deal occurring on December 3, 2025. The CEO of the company is Byeong-ju Kang.

InDream MediSupport offers a Clinical Decision Support System tailored for healthcare professionals to reduce medical disputes and facilitate medication reviews. Its flagship product, 'InDream MediSupport,' features a typing-free drug interaction checker that integrates with all electronic medical records (EMRs). This tool delivers essential drug interaction data, safety guidance for pregnancy and lactation, dosage adjustments for hepatic or renal impairment, and common side effects, significantly reducing the time needed for drug-related inquiries, thus improving patient care outcomes. The service caters to healthcare providers in the United States, Europe, and Asia, including hospitals, clinics, and individual practitioners.

InDream MediSupport generates revenue through subscription services and partnerships with healthcare institutions. Clients subscribe to access the Clinical Decision Support System, ensuring they receive regular updates on drug interaction information and safety protocols. The company also explores strategic partnerships with EMR providers to integrate its drug interaction checker into existing systems, expanding its market reach and utility, while maintaining a consistent revenue stream through its subscription model. In December 2025, InDream Healthcare secured an undisclosed amount in venture funding from Korea Tech Incubator for Startup as part of the Accelerator Investment-Driven Tech Incubator Program TIPS.

The funding will be utilized to enhance its technology and develop a global standard platform for patients. Additionally, the company plans to introduce new products and expand its presence into new markets, targeting further growth in the healthcare sector.